Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations.

The article discusses findings of a study on effects of realgar (As4S4) on degradation of promyelocytic leukemia gene (PML)-RARA fusion protein. It states role of PML-RARA as a therapy target of acute promyelocytic leukemia (APL), and mentions that arsenic trioxide cures APL by binding to the PML moiety and triggering the degradation of PML-RARA oncoprotein. It notes that most of the identified arsenic-resistance mutations were found to be located in the PML B2 domain of PML-RARA.